-
Je něco špatně v tomto záznamu ?
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
S. Katayama, VM. Schuettfort, B. Pradere, K. Mori, H. Mostafaei, F. Quhal, R. Sari Motlagh, E. Laukhtina, NC. Grossmann, A. Aydh, P. Rajwa, F. König, PI. Karakiewicz, M. Haydter, M. Moschini, M. Abufaraj, Y. Lotan, RK. Lee, QD. Trinh, E....
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2003-04-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
ROAD: Directory of Open Access Scholarly Resources
od 1997
- MeSH
- cystektomie MeSH
- hepatocytární růstový faktor terapeutické užití MeSH
- lidé MeSH
- nádory močového měchýře * patologie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- svaly patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: The HGF/MET pathway is involved in cell motility, angiogenesis, proliferation, and cancer invasion. We assessed the clinical utility of plasma HGF level as a prognostic biomarker in patients with MIBC. METHODS: We retrospectively analyzed 565 patients with MIBC who underwent radical cystectomy. Logistic regression and Cox regression models were used, and predictive accuracies were estimated using the area under the curve and concordance index. To estimate the clinical utility of HGF, DCA and MCID were applied. RESULTS: Plasma HGF level was significantly higher in patients with advanced pathologic stage and LN metastasis (p = 0.01 and p < 0.001, respectively). Higher HGF levels were associated with an increased risk of harboring LN metastasis and non-organ-confined disease (OR1.21, 95%CI 1.12-1.32, p < 0.001, and OR1.35, 95%CI 1.23-1.48, p < 0.001, respectively) on multivariable analyses; the addition of HGF improved the predictive accuracies of a standard preoperative model (+ 7%, p < 0.001 and + 8%, p < 0.001, respectively). According to the DCA and MCID, half of the patients had a net benefit by including HGF, but the absolute magnitude remained limited. In pre- and postoperative predictive models, a higher HGF level was significant prognosticator of worse RFS, OS, and CSS; in the preoperative model, the addition of HGF improved accuracies by 6% and 5% for RFS and CSS, respectively. CONCLUSION: Preoperative HGF identified MIBC patients who harbored features of clinically and biologically aggressive disease. Plasma HGF could serve, as part of a panel, as a biomarker to aid in preoperative treatment planning regarding intensity of treatment in patients with clinical MIBC.
Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada
Department of Pathology Medical University of Vienna Vienna Austria
Department of Surgery S H Ho Urology Centre The Chinese University of Hong Kong Hong Kong China
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology King Faisal Medical City Abha Saudi Arabia
Department of Urology Landesklinikum Wiener Neustadt Vienna Austria
Department of Urology Medical University of Silesia 41 800 Zabrze Poland
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Hospital Zurich Zurich Switzerland
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urological Surgery Brigham and Women's Hospital Harvard Medical School Boston USA
Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024196
- 003
- CZ-PrNML
- 005
- 20221031100328.0
- 007
- ta
- 008
- 221017s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00432-021-03887-x $2 doi
- 035 __
- $a (PubMed)34997350
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/http://orcid.org/0000000283772457
- 245 10
- $a Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer / $c S. Katayama, VM. Schuettfort, B. Pradere, K. Mori, H. Mostafaei, F. Quhal, R. Sari Motlagh, E. Laukhtina, NC. Grossmann, A. Aydh, P. Rajwa, F. König, PI. Karakiewicz, M. Haydter, M. Moschini, M. Abufaraj, Y. Lotan, RK. Lee, QD. Trinh, E. Compérat, J. Teoh, Y. Nasu, SF. Shariat
- 520 9_
- $a PURPOSE: The HGF/MET pathway is involved in cell motility, angiogenesis, proliferation, and cancer invasion. We assessed the clinical utility of plasma HGF level as a prognostic biomarker in patients with MIBC. METHODS: We retrospectively analyzed 565 patients with MIBC who underwent radical cystectomy. Logistic regression and Cox regression models were used, and predictive accuracies were estimated using the area under the curve and concordance index. To estimate the clinical utility of HGF, DCA and MCID were applied. RESULTS: Plasma HGF level was significantly higher in patients with advanced pathologic stage and LN metastasis (p = 0.01 and p < 0.001, respectively). Higher HGF levels were associated with an increased risk of harboring LN metastasis and non-organ-confined disease (OR1.21, 95%CI 1.12-1.32, p < 0.001, and OR1.35, 95%CI 1.23-1.48, p < 0.001, respectively) on multivariable analyses; the addition of HGF improved the predictive accuracies of a standard preoperative model (+ 7%, p < 0.001 and + 8%, p < 0.001, respectively). According to the DCA and MCID, half of the patients had a net benefit by including HGF, but the absolute magnitude remained limited. In pre- and postoperative predictive models, a higher HGF level was significant prognosticator of worse RFS, OS, and CSS; in the preoperative model, the addition of HGF improved accuracies by 6% and 5% for RFS and CSS, respectively. CONCLUSION: Preoperative HGF identified MIBC patients who harbored features of clinically and biologically aggressive disease. Plasma HGF could serve, as part of a panel, as a biomarker to aid in preoperative treatment planning regarding intensity of treatment in patients with clinical MIBC.
- 650 _2
- $a cystektomie $7 D015653
- 650 _2
- $a hepatocytární růstový faktor $x terapeutické užití $7 D017228
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a svaly $x patologie $7 D009132
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nádory močového měchýře $x patologie $7 D001749
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Grossmann, Nico C $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Aydh, Abdulmajeed $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Faisal Medical City, Abha, Saudi Arabia
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Medical University of Silesia, 41-800, Zabrze, Poland
- 700 1_
- $a König, Frederik $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
- 700 1_
- $a Haydter, Martin $u Department of Urology, Landesklinikum Wiener Neustadt, Vienna, Austria
- 700 1_
- $a Moschini, Marco $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, 20132, Milano, Italy
- 700 1_
- $a Abufaraj, Mohammad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan
- 700 1_
- $a Lotan, Yair $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA
- 700 1_
- $a Lee, Richard K $u Department of Urology, Weill Cornell Medical College, New York, NY, USA
- 700 1_
- $a Trinh, Quoc-Dien $u Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
- 700 1_
- $a Compérat, Eva $u Department of Pathology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Teoh, Jeremy $u Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Nasu, Yasutomo $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at
- 773 0_
- $w MED00009972 $t Journal of cancer research and clinical oncology $x 1432-1335 $g Roč. 148, č. 11 (2022), s. 3091-3102
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34997350 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100326 $b ABA008
- 999 __
- $a ok $b bmc $g 1854109 $s 1175486
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 148 $c 11 $d 3091-3102 $e 20220108 $i 1432-1335 $m Journal of cancer research and clinical oncology $n J Cancer Res Clin Oncol $x MED00009972
- LZP __
- $a Pubmed-20221017
